EcoDrugPlus

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSTTRG00000011106
Gene Symbol: ACHE
1 Cross references
233 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSTTRG00000004939
Gene Symbol: ACVRL1
1 Cross references
353 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSTTRG00000005435
Gene Symbol: ACVR2B
1 Cross references
257 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSTTRG00000009515
Gene Symbol: ADORA1
1 Cross references
269 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSTTRG00000014695
Gene Symbol: ADORA2A
1 Cross references
260 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSTTRG00000002019
Gene Symbol: ADORA2B
1 Cross references
200 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSTTRG00000013029
Gene Symbol: ADA
1 Cross references
216 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSTTRG00000004828
Gene Symbol: ADRA1A
1 Cross references
201 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSTTRG00000013016
Gene Symbol: ADRA1B
1 Cross references
263 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSTTRG00000008381
Gene Symbol: ADRB2
3 Cross references
263 Possible Orthologues:

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSTTRG00000013783
Gene Symbol: AGER
1 Cross references
169 Possible Orthologues:

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSTTRG00000002518
Gene Symbol: ADH5
1 Cross references
399 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).